research use only
Cat.No.S1718
| Related Targets | Integrase Bacterial Antibiotics Anti-infection Fungal Antiviral COVID-19 Parasite HIV HCV Protease |
|---|---|
| Other Reverse Transcriptase Inhibitors | Dapivirine (TMC120) Salicylanilide Fangchinoline Bifendate 3'-Fluoro-3'-deoxythymidine (Alovudine) Ulonivirine Lersivirine (UK-453061) 4-Chloro-2-(trifluoroacetyl)aniline hydrochloride |
|
In vitro |
DMSO
: 100 mg/mL
(199.41 mM)
Ethanol : 100 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 501.47 | Formula | C20H32N5O8P |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 142340-99-6 | Download SDF | Storage of Stock Solutions |
|
|
| Targets/IC50/Ki |
HBV RT
|
|---|---|
| In vivo |
Adefovir Dipivoxil (GS 0840) reduces Liver HBV DNA to <0.1 pg of viral DNA per mg of total DNA (pg/mg) in transgenic mice expressing hepatitis B virus. This compound also reduces serum HBV DNA to 3.5 log10 genomic equivalents (ge)/mL in the same model, compared to 5.3 log10 ge/mL for the placebo control group. Its antiviral activity reaches near maximum viral reduction by day 10 in the liver and achieves an endpoint of liver virus inhibition at 1.0 mg/kg/day.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT00489151 | Unknown status | Hepatitis B |
Hospital Authority Hong Kong|The University of Hong Kong |
June 2005 | Not Applicable |
| NCT00644761 | Completed | Hepatitis B |
Gilead Sciences |
February 2004 | Phase 2 |
| NCT00230477 | Completed | Hepatitis B |
University of Washington|Gilead Sciences|GlaxoSmithKline |
April 2003 | Phase 4 |
| NCT00158717 | Completed | Hepatitis B |
Gilead Sciences |
April 2003 | -- |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.